Pharmaceutical manufacturers are rapidly expanding active pharmaceutical ingredient facilities to meet global demand for metabolic drugs.
Supply Chain Bottlenecks
Contract manufacturing capacity remains constrained, prompting direct capital expenditure by leading drugmakers.
Economic Impact
Decreased long-term cardiovascular risks associated with these treatments may alter health insurance underwriting models.